NEW YORK CITY, NY / ACCESS Newswire / May 28, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Grace Therapeutics, Inc. ("Grace" or "the Company") (NASDAQ:GRCE). Investors who purchased Grace securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GRCE.
Grace Investigation Details
On April 23, 2026, Grace announced that "the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Company's New Drug Application (NDA) for GTx-104 for the treatment of patients with aSAH." According to the Company, "the FDA referenced certain items in the Chemistry, Manufacturing, and Controls (CMC) and Non-Clinical sections of the application," which "are related to leachables data for product packaging, non-clinical product toxicology risk assessments, and product manufacturing deficiencies at our contract manufacturing organization." Following this news, Grace's stock price dropped by nearly 45.5% on the same day.
What's Next for Grace Investors?
If you are aware of any facts relating to this investigation or purchased Grace securities, you can assist this investigation by visiting the firm's site: bgandg.com/GRCE. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
No Cost to Grace Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Grace Securities Investigation?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com
Attorney advertising.
Prior results do not guarantee similar outcomes.
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original press release on ACCESS Newswire
COMTEX_482310851/2457/2026-05-28T11:01:27